Acetylsalicylic Acid and Head and Neck Cancer: Risk, Five-Year Survival, and Recurrence in over 11,000,000 Patients-A...

Area of Science:

• Oncology
• Pharmacology
• Epidemiology

Background:

• Acetylsalicylic acid (ASA) has been hypothesized to influence cancer risk and patient survival.
• Previous research suggests a potential role for ASA in cancer prevention and treatment outcomes.

Purpose of the Study:

• To investigate the association between ASA intake and head and neck cancer (HNC).
• To evaluate the impact of ASA on HNC incidence, five-year survival rates, secondary malignancies, and lymph node involvement.

Main Methods:

• A retrospective case-control study utilizing federated electronic health record data from over 11 million patients.
• Patients were categorized into cohorts based on ASA prescription status and HNC diagnosis.
• Matched cohorts of ASA users and non-users were analyzed for HNC incidence and survival outcomes.

Main Results:

• A significantly lower incidence of HNC was observed in patients prescribed ASA (OR 0.88; 95% CI 0.86-0.90).
• Five-year survival rates were higher for ASA users (67.93%) compared to non-users (65.54%), with a statistically significant lower risk of death.
• ASA intake was associated with a reduced risk of malignant neoplasms of lymph nodes.

Conclusions:

• ASA medication appears to be associated with a reduced risk of developing HNC.
• Patients taking ASA demonstrated improved five-year survival rates and a lower likelihood of lymph node involvement.
• The retrospective nature and potential confounders necessitate further research to confirm these findings.